HomeCompareAUCCF vs MRK

AUCCF vs MRK: Dividend Comparison 2026

AUCCF yields 60606.06% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AUCCF wins by $3.261901928284439e+24M in total portfolio value
10 years
AUCCF
AUCCF
● Live price
60606.06%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.261901928284439e+24M
Annual income
$3,251,348,701,515,945,000,000,000,000,000.00
Full AUCCF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — AUCCF vs MRK

📍 AUCCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAUCCFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AUCCF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AUCCF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AUCCF
Annual income on $10K today (after 15% tax)
$5,151,515.15/yr
After 10yr DRIP, annual income (after tax)
$2,763,646,396,288,553,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, AUCCF beats the other by $2,763,646,396,288,553,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AUCCF + MRK for your $10,000?

AUCCF: 50%MRK: 50%
100% MRK50/50100% AUCCF
Portfolio after 10yr
$1.6309509641422194e+24M
Annual income
$1,625,674,350,757,972,400,000,000,000,000.00/yr
Blended yield
99.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

AUCCF
No analyst data
Altman Z
-46.2
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AUCCF buys
0
MRK buys
0
No recent congressional trades found for AUCCF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAUCCFMRK
Forward yield60606.06%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$3.261901928284439e+24M$56.8K
Annual income after 10y$3,251,348,701,515,945,000,000,000,000,000.00$9,798.13
Total dividends collected$3.2612095737392296e+24M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AUCCF vs MRK ($10,000, DRIP)

YearAUCCF PortfolioAUCCF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$6,071,306$6,060,606.06$11,206$366.19+$6.06MAUCCF
2$3,445,355,578$3,438,859,281.00$12,650$502.35+$3445.34MAUCCF
3$1,827,508,951,633$1,823,822,421,164.30$14,407$694.19+$1827508.94MAUCCF
4$906,071,602,588,717$904,116,168,010,468.80$16,585$967.82+$906071602.57MAUCCF
5$419,901,428,364,563,840$418,931,931,749,793,860.00$19,342$1,363.89+$419901428364.54MAUCCF
6$181,894,091,600,705,000,000$181,444,797,072,354,900,000.00$22,913$1,947.19+$181894091600704.97MAUCCF
7$73,651,422,736,375,290,000,000$73,456,796,058,362,524,000,000.00$27,662$2,823.89+$73651422736375280.00MAUCCF
8$27,876,627,930,516,168,000,000,000$27,797,820,908,188,250,000,000,000.00$34,159$4,173.35+$27876627930516168704.00MAUCCF
9$9,862,828,755,602,290,000,000,000,000$9,833,000,763,716,638,000,000,000,000.00$43,337$6,308.80+$9.86282875560229e+21MAUCCF
10$3,261,901,928,284,438,700,000,000,000,000$3,251,348,701,515,945,000,000,000,000,000.00$56,776$9,798.13+$3.261901928284439e+24MAUCCF

AUCCF vs MRK: Complete Analysis 2026

AUCCFStock

Goldplay Mining Inc. engages in the acquisition and exploration of mineral properties. It primarily explores for gold, silver, and copper deposits. The company holds an option agreement to acquire a 70% interest in the Scottie West gold project located in the Golden Triangle, the northwestern British Columbia; a 100% interest in the Borba 2 projects located in Portugal; and 100% interests in the Big Frank and Goldstorm South properties located in the western Chilcotin District of southwestern British Columbia. It also holds interest to acquire 100% equity interest in the Barrancos properties located in south Central Portugal. The company was formerly known as Industria Metals Inc. and changed its name to Goldplay Mining Inc. in November 2020. Goldplay Mining Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Full AUCCF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this AUCCF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AUCCF vs SCHDAUCCF vs JEPIAUCCF vs OAUCCF vs KOAUCCF vs MAINAUCCF vs JNJAUCCF vs ABBVAUCCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.